Trial Profile
An open-label, concentration controlled, randomized, 12 month study of Prograf [tacrolimus] + Rapamune [sirolimus] + cor [corticosteroids]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2009
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Tacrolimus (Primary) ; Corticosteroids
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Wyeth; Wyeth Pharmaceuticals
- 25 Aug 2009 Actual patient number (484) added as reported by ClinicalTrials.gov.
- 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2009 Actual end date (Jul 2005) added as reported by ClinicalTrials.gov.